Impact of basiliximab on the proportion of regulatory T cells and their subsets early after renal transplantation: a preliminary report.
OBJECTIVE
This study aims to investigate the impact of anti-CD25 monoclonal antibody (basiliximab) on peripheral blood regulatory T cells (Treg) and their subsets in recipients early after renal transplantation.


METHODS
Ten renal transplant recipients from November 2009 to February 2011 were divided into an induction therapy and a no-induction therapy group, mainly based on their will to accept basiliximab induction. Peripheral blood samples were collected at 2 hours before as well as 1 and 2 weeks after transplantation. Flow cytometry was used to analyze the proportion of regulatory T cells and their subsets.


RESULTS
Compared with the no-induction therapy group, the proportions of both CD25(high) T cell and CD25(high) Foxp3(+) double marked T cells were significantly decreased among in the basiliximab induction group remaining at low at 2 weeks. The subsets of activated Treg and cytokine-secreting Treg were also temporarily downregulated at 1 week after transplantation using basiliximab induction. However, the inhibitory transcriptional factor Foxp3 was not significantly affected by the induction therapy.


CONCLUSIONS
Anti-CD25 monoclonal antibody downregulated the proportion of regulatory T cell and its activated subsets in peripheral blood in the early stage after renal transplantation while the inhibitory function may still be spared.
Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, PR China.
T
T
Zhao
C
C
Yang
Y
Y
Xue
Y Y
YY
Qiu
L
L
Hu
Y
Y
Qiu
X
X
Wang
B
B
Yang
R
R
Rong
M
M
Xu
T
T
Zhu
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D016022:Case-Control Studies; D002681:China; D016207:Cytokines / Q000097:blood; D005260:Female; D005434:Flow Cytometry; D051858:Forkhead Transcription Factors / Q000097:blood; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D053645:Interleukin-2 Receptor alpha Subunit / Q000097:blood; D016030:Kidney Transplantation / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects* / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D016207:Cytokines; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; C508017:IL2RA protein, human; D007166:Immunosuppressive Agents; D053645:Interleukin-2 Receptor alpha Subunit; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab